DVAX - Dynavax Technologies Corp Stock Price, Fair Value and News

11.03USD+0.30 (+2.80%)Market Closed

Market Summary

USD11.03+0.30

Market Closed

2.80%

DVAX Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

DVAX Stock Price

View Fullscreen

DVAX RSI Chart

DVAX Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

156.55

Price/Sales (Trailing)

6.11

EV/EBITDA

68.77

Price/Free Cashflow

27.4

DVAX Price/Sales (Trailing)

DVAX Profitability

EBT Margin

3.33%

Return on Equity

1.49%

Return on Assets

0.93%

Free Cashflow Yield

3.65%

DVAX Fundamentals

DVAX Revenue

Revenue (TTM)

236.1M

Rev. Growth (Yr)

8.24%

Rev. Growth (Qtr)

-8.64%

DVAX Earnings

Earnings (TTM)

9.2M

Earnings Growth (Yr)

64.16%

Earnings Growth (Qtr)

-4.1K%

Breaking Down DVAX Revenue

Last 7 days

-5.2%

Last 30 days

-6.8%

Last 90 days

-10.2%

Trailing 12 Months

0.9%

How does DVAX drawdown profile look like?

DVAX Financial Health

Current Ratio

15.2

DVAX Investor Care

Shares Dilution (1Y)

1.87%

Diluted EPS (TTM)

0.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	236.1M	0	0	0
2023	655.6M	459.4M	361.2M	232.3M
2022	470.1M	673.8M	733.3M	722.7M
2021	119.0M	169.1M	263.9M	439.4M
2020	40.4M	34.7M	37.6M	46.6M
2019	13.8M	20.9M	30.0M	35.2M
2018	344.0K	1.5M	2.9M	8.2M
2017	8.4M	5.7M	3.0M	327.0K
2016	4.4M	5.5M	4.4M	11.0M
2015	8.2M	6.7M	5.6M	4.0M
2014	12.7M	12.3M	11.6M	11.0M
2013	10.1M	10.5M	10.9M	11.3M
2012	0	0	0	9.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dynavax Technologies Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	burgess justin	acquired	74,231	10.4537	7,101	chief accounting officer
Mar 01, 2024	burgess justin	sold	-262,322	12.78	-20,526	chief accounting officer
Feb 16, 2024	burgess justin	sold (taxes)	-29,511	12.41	-2,378	chief accounting officer
Feb 16, 2024	burgess justin	acquired	-	-	6,667	chief accounting officer
Feb 15, 2024	spencer ryan	acquired	3,798	9.45	402	ceo and director
Feb 15, 2024	novack david f	acquired	11,406	9.45	1,207	president & coo
Feb 12, 2024	janssen robert	sold (taxes)	-19,627	12.82	-1,531	svp and cmo
Feb 12, 2024	burgess justin	sold (taxes)	-32,037	12.82	-2,499	chief accounting officer
Feb 12, 2024	macdonald kelly	sold (taxes)	-38,267	12.82	-2,985	svp and cfo
Feb 12, 2024	spencer ryan	sold (taxes)	-149,789	12.82	-11,684	ceo and director

Which funds bought or sold DVAX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	OSAIC HOLDINGS, INC.	added	14.71	7,635	427,343	-%
May 10, 2024	CIBC Private Wealth Group, LLC	new	-	115,107	115,107	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-18.93	-2,514,760	6,456,740	-%
May 10, 2024	CREDIT SUISSE AG/	reduced	-0.11	-316,866	2,481,010	-%
May 10, 2024	Argent Trust Co	sold off	-100	-224,770	-	-%
May 10, 2024	Covestor Ltd	added	4.63	-	10,000	0.01%
May 10, 2024	VANGUARD GROUP INC	added	1.36	-12,993,600	116,682,000	-%
May 10, 2024	LPL Financial LLC	reduced	-73.84	-863,102	261,044	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	32,293,900	32,293,900	0.07%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	9.62	-14,737	532,874	-%

Are Funds Buying or Selling DVAX?

Are funds buying DVAX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DVAX

No. of Funds

Unveiling Dynavax Technologies Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	5.49%	7,093,214	SC 13G/A
Feb 13, 2024	vanguard group inc	7.18%	9,275,788	SC 13G/A
Jan 25, 2024	state street corp	7.35%	9,495,785	SC 13G/A
Jan 19, 2024	blackrock inc.	18.1%	23,396,930	SC 13G/A
Jan 18, 2024	federated hermes, inc.	8.79%	11,364,666	SC 13G/A
May 19, 2023	deep track capital, lp	5.10%	6,556,180	SC 13G
Feb 09, 2023	state street corp	7.83%	9,992,504	SC 13G/A
Feb 09, 2023	vanguard group inc	6.54%	8,344,862	SC 13G
Feb 01, 2023	federated hermes, inc.	9.91%	12,640,363	SC 13G/A
Jan 26, 2023	blackrock inc.	15.0%	19,086,463	SC 13G/A

Recent SEC filings of Dynavax Technologies Corp

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 05, 2024	3	Insider Trading
Apr 01, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading
Mar 12, 2024	8-K	Current Report

Peers (Alternatives to Dynavax Technologies Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	364.0B	85.6B	2.51%	-5.94%	9.46	4.25	5.68%	202.39%
MRK	327.5B	61.4B	2.84%	10.39%	142.03	5.33	6.11%	-82.30%
AMGN	165.5B	29.5B	15.44%	32.45%	43.99	5.6	12.76%	-52.47%
PFE	161.3B	57.8B	10.05%	-23.80%	128.66	2.79	76.51%	-86.81%
GILD	84.2B	27.4B	-0.76%	-13.59%	173.7	3.07	1.51%	-91.32%
TEVA	19.1B	16.0B	26.84%	110.09%	-38.64	1.19	7.23%	71.10%
MID-CAP
PRGO	4.2B	4.6B	1.52%	-12.58%	-544.93	0.92	-0.06%	94.55%
ALKS	4.2B	1.7B	1.27%	-20.64%	9.63	2.42	54.01%	364.56%
BHC	2.6B	9.0B	-18.72%	24.48%	-5.74	0.29	10.01%	-27.45%
AMPH	2.1B	676.2M	6.87%	1.73%	13.38	3.06	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	9.34%	-17.43%	-4.38	2.07	24.65%	80.36%
TXMD	23.4M	1.3M	2.01%	-53.76%	-3.16	17.98	-98.14%	-104.71%
ACRX	17.5M	-	-8.04%	33.77%	-0.95	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	5.56%	-92.40%	-0.17	0.13	80.00%	43.08%
ACOR	546.5K	117.6M	-50.00%	-97.38%	0	0	-0.79%	-283.60%

Dynavax Technologies Corp News

Latest updates

Dynavax Technologies Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-8.6%	51.00	56.00	70.00	60.00	47.00	184	168	256	114	195	108	53.00	83.00	20.00	13.00	3.00	11.00	11.00	11.00	8.00	6.00
Costs and Expenses	7.0%	69.00	64.00	64.00	64.00	77.00	121	106	128	83.00	114	92.00	44.00	55.00	31.00	27.00	26.00	30.00	38.00	41.00	47.00	44.00
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	47.00	44.00
S&GA Expenses	6.7%	44.00	41.00	38.00	37.00	37.00	31.00	32.00	36.00	32.00	29.00	27.00	22.00	22.00	18.00	22.00	19.00	21.00	20.00	18.00	18.00	18.00
R&D Expenses	-4.2%	14.00	14.00	14.00	13.00	14.00	13.00	13.00	10.00	11.00	11.00	6.00	7.00	8.00	10.00	9.00	6.00	5.00	12.00	13.00	16.00	21.00
EBITDA Margin	178.6%	0.08*	0.03*	0.20*	0.27*	0.38*	0.42*	0.46*	0.36*	0.26*	0.21*	-0.21*	-0.32*	-	-	-	-	-	-	-	-	-
Interest Expenses	0.2%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	3.00
Income Taxes	-463.4%	-2.78	1.00	-0.10	1.00	1.00	0.00	0.00	1.00	-	1.00	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-1254.3%	-11.50	1.00	14.00	4.00	-23.72	68.00	64.00	129	33.00	101	-28.43	4.00	-	-	-	-	-	-	-	-	-
EBT Margin	276.9%	0.03*	-0.02*	0.17*	0.25*	0.36*	0.41*	0.45*	0.35*	0.23*	0.18*	-0.29*	-0.45*	-	-	-	-	-	-	-	-	-
Net Income	-4082.2%	-8.72	0.00	14.00	3.00	-24.33	68.00	64.00	129	33.00	100	-28.43	4.00	1.00	-15.47	4.00	-51.58	-12.59	-36.76	-33.46	-42.71	-39.67
Net Income Margin	242.0%	0.04*	-0.03*	0.17*	0.24*	0.36*	0.41*	0.44*	0.35*	0.23*	0.17*	-0.15*	-0.03*	-	-	-	-	-	-	-	-	-
Free Cashflow	-244.7%	-17.43	12.00	31.00	27.00	26.00	33.00	60.00	14.00	-51.80	117	63.00	110	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.1%	987	997	973	936	970	986	999	1,023	1,009	1,039	920	648	490	353	353	329	259	279	301	267	297
Current Assets	-0.9%	851	859	836	797	830	917	933	955	941	973	853	584	428	290	290	265	194	209	229	191	223
Cash Equivalents	-12.0%	132	150	155	227	174	202	199	249	179	436	246	130	79.00	32.00	33.00	60.00	38.00	40.00	37.00	34.00	112
Inventory	16.0%	62.00	53.00	49.00	53.00	58.00	59.00	103	74.00	79.00	61.00	67.00	86.00	69.00	64.00	59.00	54.00	48.00	41.00	39.00	37.00	28.00
Net PPE	-2.4%	36.00	37.00	36.00	37.00	38.00	38.00	35.00	36.00	36.00	35.00	34.00	33.00	31.00	31.00	30.00	30.00	31.00	32.00	31.00	34.00	25.00
Goodwill	-2.2%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	-1.9%	368	375	368	359	406	405	499	600	721	817	852	565	390	295	284	271	247	271	262	256	253
Current Liabilities	-10.0%	56.00	62.00	54.00	45.00	92.00	150	244	345	466	556	529	205	109	77.00	67.00	53.00	29.00	53.00	46.00	45.00	42.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	220	220	180	180	180	180	180	179	178	177	176
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	220	220	180	180	180	180	180	179	178	177	176
Shareholder's Equity	-0.6%	618	622	605	577	564	581	501	423	287	222	68.00	83.00	100	59.00	69.00	58.00	12.00	8.00	39.00	11.00	43.00
Retained Earnings	-0.9%	-939	-930	-930	-945	-948	-924	-991	-1,055	-1,184	-1,217	-1,317	-1,288	-1,293	-1,294	-1,278	-1,283	-1,231	-1,218	-1,182	-1,148	-1,105
Additional Paid-In Capital	0.5%	1,562	1,555	1,542	1,528	1,516	1,511	1,502	1,485	1,476	1,442	1,386	1,373	1,394	1,352	1,349	1,343	1,246	1,229	1,224	1,161	1,151
Shares Outstanding	1.0%	131	130	129	129	128	128	126	126	125	116	115	113	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	900	-	-	-	1,100	-	-	-	1,000	-	-	-	884	-	-	-	207	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-221.2%	-16,679	13,766	31,129	28,046	27,622	34,948	61,560	16,651	-50,443	120,497	66,211	110,788	38,032	-15,743	-27,821	-21,821	-26,866	-23,012	-21,977	-36,361	-39,902
Share Based Compensation	15.1%	13,014	11,309	10,687	10,562	10,034	8,727	8,613	7,929	7,646	6,162	5,376	5,024	4,723	3,516	4,102	4,088	1,778	5,189	4,748	9,349	6,170
Cashflow From Investing	114.0%	2,831	-20,242	-106,074	24,722	-52,334	-32,967	-119,047	52,502	-216,483	54,938	45,672	-63,752	-22,633	14,342	-2,054	-49,383	10,563	24,851	-40,219	-42,027	14,613
Cashflow From Financing	-336.7%	-4,203	1,776	2,994	-294	-3,090	153	8,057	1,028	10,287	14,816	5,322	3,335	32,303	66.00	1,412	93,482	14,539	-	65,744	345	88,262

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DVAX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 50,790	$ 46,925
Operating expenses:
Cost of sales - product	10,966	14,712
Research and development	13,528	13,605
Selling, general and administrative	44,065	36,543
Bad debt expense	0	12,313
Total operating expenses	68,559	77,173
(Loss) income from operations	(17,769)	(30,248)
Other income (expense):
Interest income	9,468	6,597
Interest expense	(1,695)	(1,686)
Sublease (expense) income (Note 5)	(1,602)	1,598
Other	101	23
Net loss before income taxes	(11,497)	(23,716)
Benefit from (provision for) income taxes	2,776	(616)
Net loss	$ (8,721)	$ (24,332)
Net income per share attributable to common stockholders
Basic	$ (0.07)	$ (0.19)
Diluted	$ (0.07)	$ (0.19)
Weighted-average shares used in computing net income per share attributable to common stockholders:
Basic	130,200	127,921
Diluted	130,200	127,921
Product
Revenues:
Total revenues	$ 47,845	$ 43,451
Other Revenue
Revenues:
Total revenues	$ 2,945	$ 3,474

DVAX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 132,033	$ 150,279
Marketable securities available-for-sale	591,505	592,023
Accounts receivaAccounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at March 31, 2024 and December 31, 2023, respectively.	44,161	40,607
Other receivables	1,993	3,926
Inventories, net	61,806	53,290
Prepaid expenses and other current assets	19,788	18,995
Total current assets	851,286	859,120
Property and equipment, net	36,413	37,297
Operating lease right-of-use assets	23,392	24,287
Goodwill	2,022	2,067
Other assets	73,452	74,325
Total assets	986,565	997,096
Current liabilities:
Accounts payable	2,431	5,245
Accrued research and development	3,137	2,982
Accrued liabilities	45,841	49,448
Other current liabilities	4,593	4,520
current liabilities	56,002	62,195
Convertible Notes, net of debt discount of $2,516 and $2,802 at March 31, 2024 and December 31, 2023, respectively (Note 7)	222,984	222,698
Long-term portion of lease liabilities	28,559	29,720
CEPI accrual long-term	60,337	60,337
Other long-term liabilities	203	74
Total liabilities	368,085	375,024
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock: $0.001 par value; 278,000 shares authorized at March 31, 2023 and December 31, 2022; 128,472 shares and 127,604 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	131	130
Preferred stock: $0.001 par value; 5,000 shares authorized at March 31, 2023 and December 31, 2022; zero shares outstanding at March 31, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	1,562,027	1,554,634
Accumulated other comprehensive (loss) gain	(4,373)	(2,108)
Accumulated deficit	(939,305)	(930,584)
Total stockholders’ equity	618,480	622,072
Total liabilities and stockholders’ equity	$ 986,565	$ 997,096

About Dynavax Technologies Corp

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

CEO	Mr. Ryan Spencer
WEBSITE	dynavax.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	351

Dynavax Technologies Corp Frequently Asked Questions

What is the ticker symbol for Dynavax Technologies Corp? What does DVAX stand for in stocks?

DVAX is the stock ticker symbol of Dynavax Technologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dynavax Technologies Corp (DVAX)?

As of Mon May 13 2024, market cap of Dynavax Technologies Corp is 1.44 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DVAX stock?

You can check DVAX's fair value in chart for subscribers.

What is the fair value of DVAX stock?

You can check DVAX's fair value in chart for subscribers. The fair value of Dynavax Technologies Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dynavax Technologies Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DVAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dynavax Technologies Corp a good stock to buy?

The fair value guage provides a quick view whether DVAX is over valued or under valued. Whether Dynavax Technologies Corp is cheap or expensive depends on the assumptions which impact Dynavax Technologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DVAX.

What is Dynavax Technologies Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, DVAX's PE ratio (Price to Earnings) is 156.55 and Price to Sales (PS) ratio is 6.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DVAX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Dynavax Technologies Corp's stock?

In the past 10 years, Dynavax Technologies Corp has provided -0.017 (multiply by 100 for percentage) rate of return.